Related Experiment Videos
[Long-term administration study on TE-031 (A-56268) in the treatment of diffuse panbronchiolitis]
Abstract:
TE-031 (A-56268), a new macrolide antibiotics, was administered on a long-term basis (6 months) to 12 patients with diffuse panbronchiolitis (DPB). The causative microorganism was identified as H. influenzae in 5 cases, P. aeruginosa in 4 cases and B. catarrhalis in one case. The clinical picture of those patients was monitored, and some basic studies were also carried out. Clinically, all of the patients showed improvement in the symptoms and the various laboratory test values. Bacteriologically, as well, both H. influenzae and B. catarrhalis were eradicated. In addition, P. aeruginosa was eradicated from 2 of the 4 cases, reduced in one case and unchanged in one case. However, even in that one case in which P. aeruginosa was unchanged, the disease symptoms were alleviated. There were no instance of microbial replacement. In spite of the long-term administration of TE-031, There were no side effects. As the basic study, the DPB patients were examined for the presence of antibodies directed at viruses having affinity for the respiratory organs. It was found that a high percentage of the patients showed a high titer of antibodies for influenza virus type III and type II. It was thus surmised that it is likely that viral infection is involved in the progress of this disease. From the standpoint of the progress of DPB, the NK activity was investigated as part of the natural host defense mechanisms. It was found that, compared with healthy controls, the level of NK activity was higher in DPB patients and that it was even higher in patients on long-term TE-031 administration.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Long-term administration of the macrolide antibiotic TE-031 effectively treated diffuse panbronchiolitis (DPB) in patients, improving symptoms and reducing bacteria. This antibiotic showed no side effects and enhanced natural immune responses in DPB patients.
Area of Science:
- Respiratory Medicine
- Infectious Diseases
- Pharmacology
Context:
- Diffuse panbronchiolitis (DPB) is a chronic inflammatory lung disease.
- Bacterial infections, particularly with H. influenzae and P. aeruginosa, are common in DPB.
- Understanding the role of viral infections and immune responses in DPB is crucial.
Purpose:
- To evaluate the efficacy and safety of long-term TE-031 treatment in DPB patients.
- To assess the impact of TE-031 on bacterial eradication and clinical symptoms.
- To investigate the potential role of viral infections and NK cell activity in DPB pathogenesis and treatment response.
Summary:
- Twelve DPB patients received 6 months of TE-031, showing clinical improvement and laboratory value enhancement.
- Bacterial pathogens like H. influenzae and B. catarrhalis were eradicated; P. aeruginosa showed reduced or eradicated presence in most cases.
- No adverse effects were observed with long-term TE-031 use, and NK cell activity increased in patients, suggesting immune modulation.
Impact:
- TE-031 demonstrates significant therapeutic potential for diffuse panbronchiolitis.
- The study highlights the importance of addressing bacterial and potentially viral components in DPB.
- TE-031 may enhance host defense mechanisms, offering a novel treatment strategy for chronic respiratory diseases.